AstraZeneca highlights fresh Imfinzi approval, shares steady in FTSE 100 context

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 14:49.

AstraZeneca (US6549022043) sits in the FTSE 100 with a market value above 200 billion pounds, and its oncology franchise has delivered another regulatory milestone. On 18 June 2026 the company reported that Imfinzi-based therapy was approved in the United States for BCG-naive high-risk non-muscle-invasive bladder cancer, expanding its immuno-oncology footprint according to a Reuters report on the Imfinzi decision.

What the latest approval changes

On 18 June AstraZeneca said that the U.S. Food and Drug Administration cleared an Imfinzi combination regimen as the first immunotherapy-based option for BCG-naive high-risk non-muscle-invasive bladder cancer patients, addressing a population with limited alternatives, as reflected in the company’s oncology update and the AstraZeneca press release of 18 June 2026. The regimen targets patients ineligible for or refusing immediate cystectomy, a group where durable responses are clinically important and where AstraZeneca has focused part of its late-stage pipeline. Imfinzi, originally developed for lung cancer, has now secured approvals in multiple tumor types, and this additional label in urologic oncology broadens potential usage in U.S. hospital settings.

Regulatory clearance follows data from the NIAGARA and related bladder cancer trials, which underpin the safety and efficacy profile regulators assessed, though detailed prescribing dynamics will depend on payor decisions and clinical guideline updates referenced in U.S. oncology practice. For AstraZeneca, the extension adds another line item to its immuno-oncology revenue base alongside assets such as Tagrisso and Lynparza, reinforcing a strategy of building multi-indication franchises in checkpoint inhibition.

Analyst views and FTSE 100 positioning

London-listed AstraZeneca trades on the London Stock Exchange and is a heavyweight of the FTSE 100; MarketScreener data show the shares around 13,290 pence with a price-earnings ratio near 26 and a market capitalization slightly above 200 billion pounds as of 22 June 2026, according to the MarketScreener quote overview. Jefferies reiterated its bullish stance in mid-June, maintaining a Buy rating on the stock as noted in a 16 June 2026 analyst summary, underlining confidence in the medium-term pipeline and oncology growth drivers. In the FTSE 100 healthcare cohort, AstraZeneca is often compared with GlaxoSmithKline, but the business mix is more oncology-weighted, leading to different growth and margin expectations.

Hargreaves Lansdown data point to a trailing dividend of 1.595 pounds per share with a dividend yield of about 1.8 percent and an ex-dividend date of 19 February 2026, highlighting a policy that combines cash returns with elevated research and development outlays, as seen in the Hargreaves Lansdown share profile. For equity investors, AstraZeneca’s valuation multiple reflects expectations that oncology and rare disease assets will deliver above-sector revenue growth versus more mature primary-care portfolios in European pharma.

How AstraZeneca earns its money

AstraZeneca generates most of its revenue from prescription medicines across oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases, with oncology now the largest segment by sales according to its recent annual and first-quarter reports. Flagship products such as Tagrisso for EGFR-mutated lung cancer, Imfinzi for several tumor types, and rare disease therapies from the Alexion acquisition contribute high-margin revenue streams.

Where the stock trades today

The AstraZeneca shares (US6549022043) last traded on the London Stock Exchange at about 13,290 pence on 2026-06-22, 16:30 London time, equivalent to roughly 156.5 euros on German trading platforms at recent exchange rates.

This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Historical data and analyst assessments are not a reliable indicator of future performance. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.